In this episode of Denatured, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, ...

While you should never rely solely on AI tools when applying for jobs, they can greatly benefit the application process.

Alternatives to opioids are desperately needed to better treat moderate to severe acute pain, but to date, we’ve seen few ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral Wegovy in blood sugar control ...

Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been ...

When Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed ...

Looking for a biopharma job in San Francisco or South San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals like you.

Solstice Oncology will gain an exclusive worldwide license to Harbour BioMed’s porustobrt, an anti-CTLA-4 antibody currently being studied for melanoma, colorectal cancer and other malignancies in ...

Contract work opportunities have grown year over year, and recent reports show more people are in this type of role, according to BioSpace data. Three biopharma professionals share why they’ve become ...

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...